GSK/Vir neutralizing antibody Sotrovimab approved in the EU for early treatment of COVID-19

Compilenewborn

A few days ago, British drugmakers GlaxoSmithKline (GSK) and Vir Biotech said that the European Commission (EC) has granted Sotrovimab marketing authorization, which is sold under the Xevudy brand for the early treatment of COVID-19

As the European epidemic continues to worsen and the new Omicron variant virus emerges, Vir is confident in the key therapeutic effect of Sotrovimab, and the company looks forward to further contributing to the fight against this epidemic

This therapy is an investigational SARS-CoV-2 neutralizing monoclonal antibody that can bind to the epitope shared by SARS-CoV-2 and SARS-CoV-1 (the virus that causes SARS) on SARS-CoV-2, indicating that the epitope is highly conserved , And less likely to develop drug resistance

Currently, Sotrovimab has been approved in more than 10 countries, including the United States

Data from the Phase 3 COMET-ICE trial showed that in high-risk, newly diagnosed COVID-19 patients, sotrovimab can reduce hospitalization or mortality by 85% compared with placebo

In early December, GlaxoSmithKline and Vir Biotech announced the latest preclinical data confirming that the monoclonal antibody Sotrovimab maintains in vitro activity against the new coronavirus (SARS-CoV-2) variant Omikeron spike protein

However, whether the COVID-19 positive test data claimed by major foreign pharmaceutical companies is true has also been widely questioned by foreign people

Compared with GlaxoSmithKline’s confidence in its own products, Regeneron and Modena’s new crown drugs and vaccines have been defeated in the face of the Omicron variant

Reference source: Vir And GSK's Sotrovimab Gets EC Marketing Authorization For Early Treatment Of Covid-19